CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Kam Fai Tse(Sepragen Corporation (United States)), William J. LaRochelle(Sepragen Corporation (United States)), Ferenc Boldog(Sepragen Corporation (United States)), Suresh Shenoy(Sepragen Corporation (United States)), Gadi Gazit-Bornstein(Sepragen Corporation (United States)), Nikolai V. Khramtsov(Sepragen Corporation (United States)), Henri S. Lichenstein(Sepragen Corporation (United States)), Melanie L Shadish(Sepragen Corporation (United States)), John E. Herrmann(Sepragen Corporation (United States)), Denise A McCabe(Sepragen Corporation (United States)), Vincent A. Pollack(Sepragen Corporation (United States)), Craig Hackett(Sepragen Corporation (United States)), John R. MacDougall(Vanderbilt University), Peter D. Senter(North Carolina Central University), Michael Jeffers(Sepragen Corporation (United States)), Michael Gallo(Sepragen Corporation (United States)), Bing Kuang(Sepragen Corporation (United States)), Luca Rastelli(Sepragen Corporation (United States)), Damon L. Meyer(Seagen (United States))
Cited by 186
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772